Search

Search Constraints

You searched for: Author/Creator Stephens, Andrew

Search Results

1. [DT‐01–02]: THE IMPACT OF AMYLOID PET ON DIAGNOSIS AND PATIENT MANAGEMENT IN AN UNSELECTED MEMORY CLINIC COHORT: THE ABIDE PROJECT. (1st July 2017)

2. [IC‐01–05]: FIRST‐IN‐HUMAN PET STUDIES WITH THE NEXT GENERATION TAU AGENT 18‐F PI‐2620 IN ALZHEIMER's DISEASE, PROGRESSIVE SUPRANUCLEAR PALSY, AND CONTROLS. (1st July 2017)

3. [IC‐P‐005]: CONCORDANCE BETWEEN CEREBROSPINAL FLUID AMYLOID‐β AND [18F]FLORBETABEN PET IN AN UNSELECTED COHORT OF MEMORY CLINIC PATIENTS. (1st July 2017)

4. [IC‐P‐162]: COMPARISON OF 18F‐FLORBETABEN QUANTIFICATION RESULTS USING MR‐BASED AND MR‐LESS CAPAIBL: VALIDATION AGAINST HISTOPATHOLOGY. (1st July 2017)

5. [IC‐P‐192]: PRECLINICAL CHARACTERIZATION OF PI‐2620, A NOVEL TAU PET TRACER FOR DETECTION OF TAU IN AD AND OTHER TAUOPATHIES. (1st July 2017)

6. [P1–378]: ADDED VALUE OF FLORBETABEN PET IMAGING ON DIAGNOSIS AND MANAGEMENT IN COMPLEX CASES OF PATIENTS WITH MILD DEMENTIA ELIGIBLE FOR CSF ANALYSIS IN THE FRENCH CLINICAL PRACTICE SETTING. (1st July 2017)

7. [P1–395]: AMYPAD: A EUROPEAN PUBLIC‐PRIVATE PARTNERSHIP TO INVESTIGATE THE VALUE OF β‐AMYLOID BRAIN SCANS AS A DIAGNOSTIC AND THERAPEUTIC MARKER FOR ALZHEIMER's DISEASE. (1st July 2017)

8. [P2–207]: CONCORDANCE BETWEEN CEREBROSPINAL FLUID AMYLOID‐β AND [18F]FLORBETABEN PET IN AN UNSELECTED COHORT OF MEMORY CLINIC PATIENTS. (1st July 2017)

9. [P2–381]: PRECLINICAL CHARACTERIZATION OF PI‐2620, A NOVEL TAU PET TRACER FOR DETECTION OF TAU IN AD AND OTHER TAUOPATHIES. (1st July 2017)

10. [P4–269]: COMPARISON OF 18F‐FLORBETABEN QUANTIFICATION RESULTS USING MR‐BASED AND MR‐LESS CAPAIBL: VALIDATION AGAINST HISTOPATHOLOGY. (1st July 2017)